Insurance Weight Loss Medication Coverage: The Real Picture

You've heard about Ozempic. You've seen the results. You asked your doctor, got a prescription, and then your pharmacy told you the cost is $1,349 per month. Retail.

That's the moment most people realize that "weight loss medication" and "covered medication" are not the same thing. The gap between them is where most patients get stuck. Not because coverage doesn't exist, but because navigating it requires knowing things your insurance company isn't going to volunteer.

This guide breaks down exactly how insurance coverage for weight loss medication works: which drugs are approved for what, what insurers actually require before they'll cover them, why prior authorizations get denied, and what you can do when insurance says no.

One thing upfront: coverage varies enormously depending on your specific plan, employer, state, and diagnosis. What you read here is a framework. Your actual situation needs to be verified with your insurer and your prescriber.

---

Which GLP-1 Medications Are FDA-Approved for What

This matters more than most people realize. Insurance companies follow FDA approval status almost to the letter, and getting this wrong is one of the most common reasons prior authorizations fail.

Ozempic (semaglutide 0.5mg–2mg weekly): FDA-approved for type 2 diabetes only. Not approved for obesity. This is a critical distinction: if your diagnosis is obesity and not T2D, your insurer will almost certainly deny coverage for Ozempic, even if your doctor prescribed it specifically for weight loss. The off-label use is common but rarely covered (Powell & Taylor, 2024).

Wegovy (semaglutide 2.4mg weekly): FDA-approved for chronic weight management in adults with BMI ≥30 or ≥27 with at least one weight-related comorbidity. Also carries an FDA-approved cardiovascular risk reduction indication added in 2024. The CV indication matters: some commercial plans that previously excluded obesity coverage will cover Wegovy when cardiovascular risk reduction is the documented reason.

Mounjaro (tirzepatide 2.5mg–15mg weekly): FDA-approved for type 2 diabetes only, same situation as Ozempic. Widely prescribed off-label for weight loss, rarely covered for that indication (Powell & Taylor, 2024).

Zepbound (tirzepatide 2.5mg–15mg weekly): FDA-approved for chronic weight management (same BMI criteria as Wegovy) and for obstructive sleep apnea in adults with obesity. The OSA indication is the newest and most underutilized coverage pathway. If you have documented OSA (even mild), it's worth discussing with your prescriber because it opens a second coverage route.

The bottom line: if you're using these medications for weight loss specifically, Wegovy and Zepbound are your on-label options. Ozempic and Mounjaro are T2D drugs. Insurers know this and price their coverage decisions accordingly.

For a deeper breakdown of how these medications differ in mechanism and trial results, see our semaglutide vs tirzepatide comparison. And if you're evaluating Zepbound specifically, our Zepbound side effects guide covers what to document during your trial period.

---

What Insurance Companies Actually Require for Prior Authorization

Prior authorization for weight loss medication follows a fairly predictable pattern across commercial insurers, though exact criteria vary by plan. Here's what you'll generally need to document:

BMI threshold. Most plans require BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, hyperlipidemia, obstructive sleep apnea). This aligns with the FDA-approved indications for Wegovy and Zepbound (Brixner et al., 2008). Your prescriber documents this from your chart.

Documented diet and exercise attempt. Nearly every plan asks for evidence of a prior attempt at medically supervised weight management, typically 3 to 6 months of diet and exercise counseling with a provider. This can be documented as a referral note, visit records, or a letter from your primary care physician. The key word is "documented": verbal efforts don't count; your chart needs to show the work.

Step therapy. This is where things get frustrating. Many commercial plans and most government payers require you to try and fail older, cheaper medications before they'll approve a GLP-1. Common step therapy drugs include orlistat (Xenical/Alli), phentermine-topiramate (Qsymia), or bupropion-naltrexone (Contrave). Metformin is sometimes required as well, particularly if insulin resistance is part of the clinical picture. If you've been prescribed it previously, see our metformin side effects and usage guide for context on documenting your response. Some plans require 90 days on a step therapy drug with documented inadequate response before they'll approve semaglutide or tirzepatide. If you've tried any of these in the past, that history should be in your prior authorization documentation.

Diagnosis codes. The ICD-10 codes on your prescription and prior auth matter. For obesity: E66.01 (morbid obesity) or E66.09 (other obesity). For diabetes: E11.x series. A mismatch between the diagnosis code and the requested drug is a fast-track to denial.

Understanding these criteria before you submit (not after you get denied) dramatically improves approval rates. A 2022 review of semaglutide prescribing noted that prior authorization barriers are among the most significant access issues for this class of medications (Chao et al., 2022).

---

Step Therapy: The Part Nobody Explains Clearly

Step therapy is the requirement that you try a cheaper treatment first and show it didn't work well enough before insurance will approve the more expensive one. For weight loss medications, this means older drugs.

In practice, it plays out like this: your doctor sends in a prior authorization for Wegovy. Your insurer comes back asking for evidence that you've tried and failed orlistat, phentermine, or a similar older agent. If you haven't, they deny the PA and tell you to try the older drug for 90 days first.

There are a few ways to work through step therapy without wasting months:

If you already tried one of these older drugs at any point in the past (years ago counts), have your prescriber document it in the PA letter. "Patient tried phentermine in 2021 for 4 months with minimal response and discontinued due to cardiovascular side effects" is prior failure. Your insurer may accept it.

If you haven't tried any step therapy drugs, your fastest path through is often to document a medical contraindication. Phentermine is contraindicated in patients with certain cardiovascular conditions, uncontrolled hypertension, or hyperthyroidism. Orlistat is frequently intolerable due to GI side effects. A prescriber letter noting a specific contraindication can often substitute for a trial period.

Some states have "fail first" protection laws that limit how long step therapy can delay access to clinically appropriate medications. Whether your state has this protection depends on where you live and what type of plan you have.

---

The Most Common Denial Reasons and How to Appeal

Knowing why denials happen makes appeals far more effective.

Denial: "Not medically necessary." This is the most common. It usually means the documentation didn't clearly connect the medication to a covered indication. The appeal response: a letter from your physician explaining how the patient meets BMI and comorbidity criteria, plus any studies showing clinical benefit in this population. Chao et al. (2022) documented average weight losses of 9.6–17.4% of initial body weight with semaglutide at 68 weeks. That's data worth including in an appeal letter. A real-world pragmatic trial (Buse et al., 2023) confirmed that semaglutide's weight and glycemic benefits hold in everyday clinical settings, not just controlled research conditions, which is useful context for a peer-to-peer review. If your appeal involves semaglutide specifically, having current documentation of Ozempic or Wegovy side effects and tolerability can also support the case that your provider monitored your response appropriately.

Denial: "Step therapy not completed." This is resolvable if you have any prior history with cheaper weight loss medications. Gather chart notes, old prescriptions, or pharmacist records. If no prior history, explore contraindication documentation.

Denial: "Drug not covered by plan." Some plans simply exclude anti-obesity medications from their formulary. This isn't a PA denial. It's a coverage exclusion. Appeals here are harder. Your options are: employer plan change request, state insurance department complaint (if your state has anti-obesity medication coverage mandates), or escalation to external review.

Denial: "BMI doesn't meet threshold." This sometimes happens when the wrong BMI is documented, or when height and weight measurements in the chart don't match the claim. Have your prescriber resubmit with current, in-office measurements.

For any denial, you have the right to:

1. Request a peer-to-peer review, where your doctor speaks directly with the insurance company's medical reviewer
2. File an internal appeal (most plans give you 30–60 days)
3. File an external appeal with an independent organization if the internal appeal fails
4. File a complaint with your state insurance commissioner

The peer-to-peer review is often underused and frequently effective. Physicians who request it are usually speaking with a clinician who understands the evidence, not a claims processor following a checklist.

---

The CVS Caremark Situation with Zepbound

In early 2025, CVS Caremark made headlines when it announced formulary changes that removed Zepbound from preferred coverage status for some plans, favoring Wegovy in that tier instead. This affected patients who had existing Zepbound coverage through CVS Caremark-administered plans.

The practical impact: if your employer uses CVS Caremark as their pharmacy benefit manager (PBM) and you were on Zepbound, you may have received a letter saying your drug was moving to a non-preferred tier, or that coverage was ending at renewal.

The formulary switch illustrates a broader pattern: pharmacy benefit managers increasingly drive coverage decisions for this drug class, and individual plan structures vary significantly (Roser et al., 2022). If this happened to you, your options are:

Request a formulary exception. Your prescriber submits a letter explaining why Zepbound is medically necessary for you specifically, compared to the preferred alternative (Wegovy). If you've already responded well to tirzepatide dosing, or if you have the OSA indication, that's a reasonable medical necessity argument.

Appeal directly. CVS Caremark has an appeals process separate from your insurance company.

Consider switching to Wegovy. Semaglutide and tirzepatide have different mechanisms and different average outcomes for different people. Some patients switch and do just as well; others don't. This is a conversation worth having with your prescriber before assuming you must stay on tirzepatide.

---

Medicare and Medicaid: The Real Coverage Picture

This is where the news is mostly bad, with a few exceptions.

Traditional Medicare (Parts A and B) has historically not covered weight loss medications for obesity. Part D prescription drug coverage also excluded anti-obesity medications as a drug class for decades. The Treat and Reduce Obesity Act, a bill that would change this, has been introduced and reintroduced in Congress multiple times without passing as of early 2026.

Medicare exception for cardiovascular indication: Wegovy's 2024 FDA approval for cardiovascular risk reduction in patients with established cardiovascular disease opened a narrow coverage window. CMS (the Centers for Medicare & Medicaid Services) announced in 2024 that Medicare Part D plans may cover semaglutide 2.4mg (Wegovy) specifically for the CV risk reduction indication. This is not obesity coverage. It's cardiovascular coverage. You need documented cardiovascular disease plus obesity. If that's your situation, ask your prescriber explicitly about documenting the CV indication on your prior authorization.

Medicaid coverage varies dramatically by state. Some states (like Pennsylvania and New York) have expanded Medicaid coverage for anti-obesity medications. Others cover GLP-1s only for type 2 diabetes, not obesity. A 2022 analysis highlighted that only about 12% of adults with obesity received any anti-obesity pharmacotherapy, compared to 86% of adults with diabetes receiving glucose-lowering medications. Roser et al. (2022) attributed this gap directly to coverage inequities. Checking your state's Medicaid preferred drug list is the only way to know where you stand.

VA coverage is more progressive on this front. Veterans with a diagnosis of obesity (BMI ≥30) and at least one obesity-related condition are generally eligible for GLP-1 medications through VA formularies, subject to prescriber approval and availability. A survey of primary care providers found that most recognized obesity as a clinical priority but rarely prescribed medications for it, a pattern rooted partly in coverage uncertainty (Falvo et al., 2017).

---

State Coverage Mandates: A Patchwork

About a dozen states have enacted laws requiring health insurance plans to cover anti-obesity medications, but the specifics vary considerably. Insurance coverage patterns can reflect social attitudes toward weight and medication, not just clinical criteria — coverage decisions aren't always purely evidence-based (Post & Persky, 2024). Arkansas, Illinois, and several others have specific mandates. These typically apply to state-regulated fully insured plans, not to self-funded employer plans (which are regulated under federal ERISA law and not subject to state mandates).

If you're in a state with a coverage mandate and your employer-sponsored plan is fully insured, you may have stronger standing to appeal a denial. If you're in a self-funded plan (which covers most employees at large companies), state mandates generally don't apply.

Your HR department can tell you whether your plan is fully insured or self-funded. It's worth asking before you assume state protections apply.

---

Self-Pay Alternatives When Insurance Won't Cover It

Retail pricing for GLP-1 medications runs $1,000–$1,400 per month without any assistance. That's not sustainable for most people. Here's what actually exists to reduce that cost:

Manufacturer savings cards. Novo Nordisk offers the Wegovy Savings Card, which can bring monthly costs as low as $25 for eligible commercially insured patients (not Medicare or Medicaid). Tsai et al. (2006) noted that less than half of commercial insurance plans consistently covered weight loss treatments, a gap that savings card programs were designed to partially address. Eli Lilly has a similar Zepbound savings card. These cards don't work if your insurance covers the drug. They're for patients whose insurance denies coverage or doesn't include the medication. Eligibility requirements and savings amounts change; verify directly with the manufacturer's patient support line.

Eli Lilly Direct. Eli Lilly launched a direct-to-patient program (LillyDirect) that provides Zepbound at a fixed monthly cost, bypassing the traditional pharmacy system. As of early 2026, this has been an option for patients who cannot get insurance coverage. Pricing has been set significantly below retail. You do need a valid prescription.

Compounded GLP-1 medications. During periods of FDA-declared drug shortage for semaglutide and tirzepatide, compounding pharmacies were legally permitted to produce compounded versions of these active pharmaceutical ingredients at significantly lower cost (sometimes $200–$500/month). Powell & Taylor (2024) noted that off-label and compounded prescribing surged precisely because insurance coverage remained unavailable for the obesity indication while patients sought any access pathway they could find. As of mid-2025, FDA moved to end the shortage designations, which affects the legal status of compounded versions. This is an evolving regulatory area. Compounded versions are not FDA-approved, which means no clinical trial data supports their specific formulation, and quality can vary significantly between compounding pharmacies. If you're considering this route, work with a licensed prescriber who can vet the pharmacy and monitor your response. Do not source from unvetted online pharmacies.

360-day supply programs. Some telehealth platforms and pharmacies offer extended supply arrangements that reduce per-dose cost. These vary by state and provider.

The cost picture is genuinely difficult. A 2022 review noted insurance coverage and cost as two of the most significant considerations for prescribers when selecting semaglutide for patients, not just efficacy (Chao et al., 2022).

---

How to Get GLP-1 Medication Through Insurance: A Step-by-Step Approach

The process is not intuitive. Here's what actually works, in order:

Step 1: Know your plan's drug formulary before your appointment. Log into your insurance portal and search for Wegovy, Zepbound, Ozempic, or Mounjaro. This tells you whether the drug is covered at all, what tier it's on, and what the estimated cost-share is. Do this before you go to your doctor so you can have an informed conversation about which medication to target.

Step 2: Confirm your diagnosis is properly documented. Your chart needs a clear obesity or metabolic syndrome diagnosis with a current BMI measurement. If your previous visits only have weight listed as a note rather than a diagnosis code, ask your prescriber to add the appropriate ICD-10 code.

Step 3: Document any prior weight management efforts. Even if it was a diet program years ago, a referral to a dietitian, or a brief trial of any anti-obesity medication, get it documented in your chart. The insurance company will ask.

Step 4: Submit a thorough prior authorization. Don't let the PA go in as just a prescription. The Why WAIT program, which achieved 82% HbA1c improvement in diabetic patients through structured weight management, showed that well-documented clinical programs are generally covered, and that documentation depth matters for payer approval (Hamdy & Carver, 2008). The same principle applies to GLP-1 prior authorizations. Your prescriber's office should include a clinical note explaining your BMI, comorbidities, prior treatment history, and why this specific medication is appropriate. A one-page clinical letter significantly improves approval rates versus a bare PA form.

Step 5: If denied, don't assume it's final. First-pass denial rates for weight loss medications run high. In some analyses, over 50% of initial PAs are denied. The key is that persistence often works. Request the peer-to-peer review. File the internal appeal with additional documentation. If you can document worsening of comorbidities (blood pressure, HbA1c, lipids) while waiting for coverage, include that.

---

Frequently Asked Questions

Does Ozempic insurance coverage work for weight loss even if I don't have diabetes?

No, not typically. Ozempic is FDA-approved for type 2 diabetes, and most insurance plans will only cover it for that indication. If your prescription is written for weight loss with an obesity diagnosis and no T2D, expect a denial. Wegovy (semaglutide 2.4mg) is the FDA-approved version for weight management and has better odds of coverage for that indication, though it still requires prior authorization.

Can an OB-GYN or gynecologist prescribe weight loss medication?

Yes. Any licensed physician or advanced practice provider (NP, PA) with prescribing authority can prescribe GLP-1 medications, including OB-GYNs. This is relevant for women whose primary ongoing care is with their gynecologist. There's no requirement to see an endocrinologist or obesity medicine specialist, though a specialist can be helpful if insurance appeals are needed.

What do I do if my BMI dropped and my insurance stopped covering my medication?

This is a real and increasingly common situation. As people lose weight on GLP-1 medications, their BMI can fall below coverage thresholds. Some insurers use this as grounds to discontinue coverage. Your appeal argument: the medication is working, discontinuing it causes medically documented weight regain, and the weight loss itself reduced the comorbidities that warranted coverage in the first place. Include any literature your prescriber can cite on weight regain after GLP-1 discontinuation.

How do I handle losing Zepbound coverage due to the CVS Caremark formulary change?

Request a formulary exception immediately (your prescriber submits this). The basis is medical necessity. If you've responded well to tirzepatide specifically and switching to semaglutide would require starting over with dose titration and uncertain response, that's a clinically reasonable exception request. If the exception is denied, file an appeal and consider having your prescriber document any clinical reasons tirzepatide is preferred for your specific case (OSA diagnosis, prior semaglutide history, etc.).

Are compounded GLP-1 medications safe?

The active pharmaceutical ingredient is the same, but the FDA hasn't reviewed the formulation, manufacturing processes, or dosing protocols for compounded versions. Quality varies significantly between compounding pharmacies. Some legitimate 503B compounding pharmacies operate under stricter standards than traditional compounders. If this route is being considered, work with a prescribing physician who has vetted the specific pharmacy and who will monitor your response and bloodwork. Do not source medications from unverified online pharmacies.

---

Cost, Coverage, and Access Through HEXIS

Insurance weight loss medication coverage is complicated by design. Tsai et al. (2006) documented that less than 50% of insurance plans covered weight loss medications even two decades ago. The situation today, despite better medications, remains inconsistent.

At HEXIS Health, your path to GLP-1 medication starts with a full metabolic workup. Your weight, BMI, comorbidities, fasting glucose, HbA1c, lipid panel, and thyroid function all matter. Not just because they're clinically relevant, but because they're the documentation your insurance company will ask for during prior authorization.

We've walked patients through this process many times. We know what documentation improves PA approval rates. We know when an appeal is worth pursuing and when it's better to find a self-pay alternative. And we can help you understand all of your options, including manufacturer savings cards and legitimate compounding, if insurance isn't workable for your situation.

If you've been trying to figure out how to get your insurance weight loss medication covered, start with a consultation. The protocol is built around your labs and your actual situation, not a template.

Schedule a consultation

---